Tebentafusp-Tebn (Kimmtrak®) for HLA-A*02:01-Positive Unresectable or Metastatic Uveal Melanoma

Tebentafusp-tebn (Kimmtrak®) is a bispecific T-cell engager approved for HLA-A∗02:01-positive unresectable or metastatic uveal melanoma. In a Phase III trial with 378 patients, tebentafusp showed a 1-year overall survival rate of 73% compared to 59% for the control group, and a 6-month progression-free survival rate of 31% versus 19%. Common side effects include cytokine release syndrome, rash, and fatigue, with Grade ≥3 adverse events in 44% of tebentafusp patients. The drug is administered intravenously with no required premedications, though corticosteroids can be used for moderate cytokine release syndrome. Monitoring for cytokine release syndrome is crucial, especially during the first three doses.